These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 37047385)
1. Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias. Sharma R; Singh S; Whiting ZM; Molitor M; Vernall AJ; Grimsey NL Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047385 [TBL] [Abstract][Full Text] [Related]
2. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263 [TBL] [Abstract][Full Text] [Related]
3. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationships of diindolylmethane derivatives as cannabinoid CB Mahardhika AB; Ressemann A; Kremers SE; Gregório Castanheira MS; Schoeder CT; Müller CE; Pillaiyar T Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200493. PubMed ID: 36437108 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563 [TBL] [Abstract][Full Text] [Related]
7. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists. Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877 [TBL] [Abstract][Full Text] [Related]
8. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway. Dhopeshwarkar A; Mackie K J Pharmacol Exp Ther; 2016 Aug; 358(2):342-51. PubMed ID: 27194477 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816 [TBL] [Abstract][Full Text] [Related]
10. Characterization of structurally novel G protein biased CB Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808 [TBL] [Abstract][Full Text] [Related]
11. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor. Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003 [TBL] [Abstract][Full Text] [Related]
12. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874 [TBL] [Abstract][Full Text] [Related]
13. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists. Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913 [TBL] [Abstract][Full Text] [Related]
14. Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines. Oyagawa CRM; de la Harpe SM; Saroz Y; Glass M; Vernall AJ; Grimsey NL Front Pharmacol; 2018; 9():1202. PubMed ID: 30524271 [TBL] [Abstract][Full Text] [Related]
15. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227 [TBL] [Abstract][Full Text] [Related]
16. RAMP and MRAP accessory proteins have selective effects on expression and signalling of the CB Glenn NAK; Finlay DB; Carruthers ER; Mountjoy KG; Walker CS; Grimsey NL Br J Pharmacol; 2024 Jul; 181(14):2212-2231. PubMed ID: 37085333 [TBL] [Abstract][Full Text] [Related]
17. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain. Deng L; Cornett BL; Mackie K; Hohmann AG Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. Ford BM; Franks LN; Radominska-Pandya A; Prather PL PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172 [TBL] [Abstract][Full Text] [Related]
19. Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence. Ibsen MS; Finlay DB; Patel M; Javitch JA; Glass M; Grimsey NL Front Pharmacol; 2019; 10():350. PubMed ID: 31024316 [TBL] [Abstract][Full Text] [Related]
20. Structure-kinetic relationship studies of cannabinoid CB Soethoudt M; Hoorens MWH; Doelman W; Martella A; van der Stelt M; Heitman LH Biochem Pharmacol; 2018 Jun; 152():129-142. PubMed ID: 29574067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]